Development and production of clinical-grade biopharmaceuticals
Official title: DCP - Biopharmaceutical Development Program (BDP) Support
Funded at Leidos Biomedical Research, INC. · NIH-11219801 · Data updated 2026-11-12
This study is all about making safe and effective new medicines, like vaccines and treatments for various conditions, so that patients can have access to the latest therapies that meet high-quality standards.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Leidos Biomedical Research, INC. NIH-funded |
| Lab location | 1 site (Frederick, United States) |
| Project start | September 28, 2024 |
| Project end | August 30, 2025 |
| Funding year | 2024 |
| Award (this year) | $965,760 |
| NIH project number | 75N91019D00024-0-759102400011-24 |
| Project ID | NIH-11219801 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for participation or benefit from this research include individuals with conditions that may be treated by the biopharmaceuticals being developed, particularly those involved in early-phase clinical trials.
✕Less likely to help
Patients who do not have conditions targeted by the biopharmaceuticals being developed or who are not eligible for clinical trials may not receive any benefit from this research.
What this research studies
This research focuses on the Biopharmaceutical Development Program (BDP), which operates a facility dedicated to creating clinical-grade biopharmaceuticals such as monoclonal antibodies, vaccines, and cell therapies. The program emphasizes compliance with FDA regulations and Good Manufacturing Practices to ensure the safety and efficacy of these products. Patients may benefit from the development of new treatments that are produced under stringent quality standards, potentially leading to innovative therapies in clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to the availability of new and effective biopharmaceutical treatments for various conditions.
How similar studies have gone: Other research in biopharmaceutical development has shown success in producing effective treatments, indicating that this approach is both established and promising.
Where this research is happening
-
Leidos Biomedical Research, INC.
Frederick, United States Active
Researchers
- Principal investigator: Briscoe, Lynn — Leidos Biomedical Research, INC.
- Study coordinator: Briscoe, Lynn
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.